TLX101-CDx is an investigational positron emission tomography agent that targets the membrane transport proteins, LAT1 and LAT2.

Phase 2b study evaluating diagnostic performance of 18F-RAD101 for suspected recurrent brain metastases from solid tumors of different origins. Underscores Radiopharm’s commitme ...

There is a positive association between exposure to at least 1 head/neck CT scan and the risk for pediatric brain tumors.

The solid cash conversion allows Telix to internally fund organic growth and flexibility to pursue acquisitions. We expect the company to reinvest the majority of earnings into R&D. We forecast ...

Radiation from the images causes 5 percent of cancer cases, according to a new study. The doctor who made this grim discovery ...

Telix (ASX:TLX) has copped a sharp jab on Monday as the FDA says its drug TLX101-CDx, AKA Floretyrosine, can’t be accepted ...

Telix has been shocked by the US Food & Drug Administration's rejection of marketing approval for its brain cancer diagnostic ...

Researchers have developed an AI system that predicts brain tumor recurrence in children using sequential MRI scans. By ...

Researchers have developed an AI model that analyzes sequences of brain scans to accurately predict tumor recurrence in children with gliomas.

Researchers trained and validated a deep learning model that can detect subtle changes across post-treatment brain scans and forecast glioma recurrence with up to 89 percent accuracy.

Artificial intelligence (AI) shows tremendous promise for analyzing vast medical imaging datasets and identifying patterns that may be missed by human observers.